NuCana PLC (NASDAQ:NCNA) has received an average rating of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $24.00.

Several equities research analysts have recently commented on NCNA shares. Cowen reissued a “buy” rating on shares of NuCana in a research note on Wednesday, August 29th. Zacks Investment Research raised NuCana from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research note on Thursday. Finally, ValuEngine raised NuCana from a “hold” rating to a “buy” rating in a research note on Tuesday.

NCNA traded down $0.27 during trading on Friday, reaching $19.51. The company’s stock had a trading volume of 67,689 shares, compared to its average volume of 80,730. NuCana has a 52-week low of $9.32 and a 52-week high of $32.00. The firm has a market capitalization of $792.73 million and a PE ratio of -18.41.

NuCana (NASDAQ:NCNA) last announced its quarterly earnings data on Tuesday, August 28th. The company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.19. On average, equities analysts predict that NuCana will post -0.91 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Woodford Investment Management Ltd boosted its stake in shares of NuCana by 27.3% during the 2nd quarter. Woodford Investment Management Ltd now owns 420,000 shares of the company’s stock worth $7,980,000 after acquiring an additional 90,000 shares in the last quarter. Asymmetry Capital Management L.P. boosted its stake in shares of NuCana by 18.4% during the 2nd quarter. Asymmetry Capital Management L.P. now owns 47,872 shares of the company’s stock worth $910,000 after acquiring an additional 7,424 shares in the last quarter. Sofinnova Ventures Inc purchased a new stake in shares of NuCana during the 1st quarter worth approximately $88,293,000. Alps Advisors Inc. boosted its stake in shares of NuCana by 8.2% during the 2nd quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock worth $879,000 after acquiring an additional 3,508 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its stake in shares of NuCana by 2.2% during the 2nd quarter. Baillie Gifford & Co. now owns 655,450 shares of the company’s stock worth $12,454,000 after acquiring an additional 14,330 shares in the last quarter. 24.42% of the stock is currently owned by institutional investors and hedge funds.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

Featured Article: Technical Analysis of Stocks, How Can It Help

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.